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 Response 
 We thank Drs Bregni and Pedrazzoli, who 
are both members of the European Blood 
and Marrow Transplantation group, to 
give us another chance to emphasize that 
high-dose chemotherapy is clearly toxic 
and not superior to standard chemotherapy 
for the treatment of small-cell lung cancer 
(SCLC) and that the medical community 
should put its energy and money in new 
treatment approaches. Drs Bregni and 
Pedrazzoli suggest that some limitations of 
the study, eg, low patient number, high 
toxic death rate, low compliance in the 
high-dose arm, and weak subgroup analy-
ses, might have contributed to the null 
findings . Indeed, the points they have raised 
in no way affect any part of the study or of 
the conclusions that we hereby confirm and 
stand by. 
 The design modiﬁ cation was made pri-
marily because of slow accrual and without 
any prior knowledge of the accumulating 
evidence. The sequential design that was 
eventually adopted controlled the probabil-
ity of an erroneous conclusion of the same 
magnitude as the original ﬁ xed sample 
design. The sample size to be reached if the 
trial had not stopped at any of the three 
interim analyses would have been larger 
than initially planned: This was the price to 
pay to allow for a sequential design. Thus, 
the change in design and a legitimate 
interim analysis cannot be considered as 
possible causes for missing a potentially 
real effect. Virtually no clinical trial is 
designed to test the interaction between 
treatment and prognostic factors, and ours 
was no exception. We may have provided 
stronger evidence, but deﬁ nitely no reliable 
answer, to the question of beneﬁ t to sub-
groups, because our study would not have 
had the statistical power for that purpose, 
even if it had reached the full sample size. 
 When we presented data on relative 
dose intensity of the high-dose arm, we did 
so considering the actual drug dose and 
schedule that was received by each patient 
in relation to the intended protocol dose of 
the standard dose arm for that patient. We 
therefore can indeed claim an average 
threefold increase in dose, despite the fact 
that some patients did not receive complete 
treatment. Moreover, the compliance to 
the standard dose was also far from being 
complete. 
 Concerning the evidence supporting 
intensiﬁ cation in SCLC, the picture is not 
nearly as optimistic as Drs Bregni and 
Pedrazzoli suggest. Their conclusion in a 
recent publication ( 1 ) is that there is no evi-
dence to support the use of high-dose che-
motherapy in solid tumors, except, maybe, 
for breast cancer. Should there be a promis-
ing and less toxic chemotherapy, we would 
agree with Drs Bregni and Pedrazzoli that 
it would deserve attention, but this option 
is not on the horizon for SCLC thus far 
and even if it was, it would have to with-
stand competition from other, at least as 
interesting, novel therapeutic alternatives, 
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as suggested by Dr Bunn in his very sup-
portive editorial ( 2 ) discussing our paper. 
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